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Abstract
Tobacco and alcohol use are linked behaviors that individually and synergistically increase the risk 
for negative health consequences. This study was a two-group, randomized clinical trial evaluating 
the efficacy of a behavioral intervention, “Motivation And Problem Solving Plus” (MAPS+), 
designed to concurrently address smoking cessation and the reduction of at-risk drinking. Targeted 
interventions may promote coaction, the likelihood that changing one behavior (smoking) 
increases the probability of changing another behavior (alcohol use). Puerto Ricans (N=202) who 
were smokers and at-risk drinkers were randomized to standard MAPS treatment focused 
exclusively on smoking cessation (S-MAPS), or MAPS+, focused on cessation and at-risk 
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drinking reduction. Drinking outcomes included: number of at-risk drinking behaviors, heavy 
drinking, binge drinking, and drinking and driving. MAPS+ did not have a significant main effect 
on reducing at-risk drinking relative to S-MAPS. Among individuals who quit smoking, MAPS+ 
reduced the number of drinking behaviors, the likelihood of meeting criteria for heavy drinking 
relative to S-MAPS, and appeared promising for reducing binge drinking. MAPS+ did not 
improve drinking outcomes among individuals who were unsuccessful at quitting smoking. MAPS
+ showed promise in reducing at-risk drinking among Puerto Rican smokers who successfully quit 
smoking, consistent with treatment enhanced coaction. Integrating an alcohol intervention into 
cessation treatment did not reduce engagement in treatment, or hinder cessation outcomes, and 
positively impacted at-risk drinking among individuals who quit smoking. Findings of coaction 
between smoking and drinking speak to the promise of multiple health behavior change 
interventions for substance use treatment and chronic disease prevention.
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1. Introduction
Smoking and problematic alcohol use are both major risk factors for death and chronic 
disease. For example, almost one-third of all cancers and cardiovascular disease in the U.S. 
are directly attributable to smoking1,2 and 10% of deaths are attributable to excessive 
alcohol use 3,4. Not only are tobacco and alcohol use major public health problems 
individually, they are clustered within individuals5 and the simultaneous use of both 
substances synergistically increases the risk for chronic disease and mortality6-8. Moreover, 
these negative consequences are not limited to only heavy use. Light smoking increases 
cancer risk as does “at-risk” drinking9. At-risk drinking, as defined by the Institute of 
Medicine and the National Institute on Alcohol Abuse and Alcoholism, is characterized by 
engaging in chronic moderate or high levels of use and/or frequent binge drinking, and is 
related to numerous negative health and social consequences10-12.
Fortunately, the risk for various diseases and other negative health consequences declines 
following smoking cessation and the reduction of alcohol use13-15. Thus, a critical strategy 
for chronic disease prevention is to reduce the use of these two substances. National 
recommendations include integrating screening and treatment of tobacco use and at-risk 
drinking into health-related settings12,16. Further, because the clustering of smoking and 
drinking increases disease risk, treatment costs, and public health burden, there is an urgent 
need for interventions designed to change multiple risk factors17. Some research suggests 
that multiple risk behavior interventions are cost effective, efficacious, and well 
received18,19. In addition, research on multiple health risk behaviors is increasingly 
emphasizing the study of coaction, defined as the likelihood that change in one behavior 
increases the probability of change in a second behavior20,21. Importantly, coaction is more 
likely to occur in the context of targeted interventions addressing the behaviors of interest, 
indicating that coaction can be induced via treatment. However, few studies have evaluated 
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coaction between smoking and at-risk drinking either via treatment or as part of the natural 
history of change in these behaviors22-25.
Combined treatments for smoking and alcohol use have been primarily conducted among 
individuals who were in treatment for alcohol abuse/dependence, with smoking as a 
secondary target of treatment26. However, the few studies that have evaluated interventions 
that add treatment for nondependent alcohol use to smoking cessation treatment have 
yielded promising results for both smoking and drinking outcomes27,28. Given that 
approximately half of all smokers attempt to quit each year29, introducing alcohol risk 
reduction into smoking cessation treatments could be an effective approach to increasing the 
impact of substance use treatment and chronic disease prevention efforts.
Motivational enhancement and problem solving/coping skills training are empirically 
supported treatments for both smoking and problematic alcohol use16,30,31, and 
recommendations have been made for the integration of these approaches32,33. Motivation 
And Problem Solving (MAPS) is an intervention that combines attributes of both 
approaches16,34,35 to address the consideration, initiation, and maintenance of behavior 
change36. MAPS utilizes a Wellness Program that is developed in collaboration with the 
participant. The Wellness Program addresses treatment goals related to behavior change as 
well as other salient concerns for the participant such as mood and contextual factors36. 
Compared to approaches that emphasize stages or phases of change37, MAPS conceptualizes 
motivation for behavior change and maintenance as a dynamic and fluid process that varies 
from moment to moment depending on both individual and contextual factors36. 
Randomized clinical trials have demonstrated that MAPS and its precursors are effective 
interventions for improving smoking related outcomes including promoting a quit attempt, 
cessation, and relapse prevention38-40.
The current study evaluated the efficacy and coaction potential of using MAPS to address 
both smoking cessation and reduction of at-risk alcohol use among Puerto Rican smokers 
who were also at-risk drinkers. Like the general population of the U.S., tobacco and alcohol 
use are major public health problems in Puerto Rico (PR). Although the adult prevalence of 
smoking in PR is lower (14.8%) than the prevalence of smoking in the U.S. (18.1%)41,42, 
three (heart disease, cancer and cerebrovascular disease) of the five leading causes of death 
in PR are associated with smoking43. Similarly, although Puerto Ricans living in PR are less 
likely to drink than are either the general population or Latinos in the U.S., those who do 
drink are more likely to be binge drinkers44. Thus, reducing both smoking and drinking is 
crucial to disease prevention in this population.
A standard MAPS treatment (S-MAPS) focused on smoking cessation alone was compared 
to an enhanced MAPS intervention (MAPS+) that addressed both smoking cessation and the 
reduction of at-risk drinking behaviors. MAPS+ was hypothesized to be more effective than 
S-MAPS at reducing at-risk drinking and to produce greater coaction such that individuals 
who quit smoking would be more likely to also reduce at-risk drinking behaviors. Similar to 
coaction metrics in previous research23, in our study coaction was evidenced by individuals 
indicating change in a second behavior (e.g. at-risk drinking) after successfully changing an 
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initial behavior (e.g. smoking). S-MAPS and MAPS+ were hypothesized to be equally 
effective with respect to smoking cessation.
2. Methods
2.1. Participants
The study was a two-group randomized clinical trial (RCT) conducted among 202 Puerto 
Rican smokers who were attempting to quit smoking and who were also at-risk drinkers. 
Inclusion criteria were: current daily smoker interested in quitting smoking in the next 30 
days, aged ≥ 18 years, resident of PR, having a working telephone number and home 
address, no other household members enrolled in the study, and meeting at least one at-risk 
drinking criterion in the past 30 days [average of ≥ 2 drinks per day (males) or ≥ 1 drink per 
day (females); two or more occasions of consuming ≥ 5 drinks (males) or ≥ 4 drinks 
(females); or one or more occasions of driving after consuming ≥ 3 drinks]11,12. Exclusion 
criteria were: currently pregnant, currently incarcerated, or having a score of ≥16 on the 
Alcohol Use Disorders Identification Test45, which indicated a probable alcohol use disorder 
and the need for more than brief counseling. Major causes of ineligibility included not 
meeting criteria for at-risk drinking (37%) or scoring 16 or above on the AUDIT (62%). 
Individuals excluded from the study due to high AUDIT scores were given referral for more 
intensive alcohol treatment.
2.2. Procedures
This trial was registered on the United States National Institutes of Health Clinical Trials 
Registry, and was approved by the Institutional Review Board.
Potential participants were recruited through the Puerto Rico Quitline (PRQ) and via local 
newspaper advertisements in PR. Individuals were screened for eligibility by phone, and 
eligible participants were scheduled for a Baseline assessment call. All individuals who were 
ineligible, withdrew from the study, or chose not to participate, remained eligible for free 
smoking cessation treatment from the PRQ. Baseline assessments were conducted following 
verbal informed consent procedures (i.e. audiotaped, encrypted, and stored in password 
protected files). Enrollment spanned September 2009 through May 2011. After the Baseline 
assessment call, participants were randomly assigned to S-MAPS or MAPS+ using a 
computer-generated form of adaptive randomization called minimization46,47. Compared to 
techniques such as stratification, minimization results in a better group balance with respect 
to participant characteristics. Minimization also provides for balanced treatment groups 
throughout the randomization process and extended accrual periods. The variables used for 
minimization randomization were: age, gender, cigarettes/day, drinks/day and depressive 
symptoms (as measured by The Center for Epidemiologic Studies Depression Scale48. 
Blinded follow-up assessments were conducted via telephone at weeks 12, 26 and 52 after 
Baseline. Study procedures were conducted in Spanish. Different personnel functioned as 
counselors and assessors. Participant's compensation (gift cards up to $100) was for data 
collection only and was not associated with treatment. Figure 1 shows participant flow.
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Counselor selection criteria and training were consistent with several major national clinical 
trials evaluating motivational interviewing-based approaches and with real world quitline 
counselors49,50. Five counselors provided the treatments. All counselors had a masters or 
doctoral degree in counseling or psychology, at least two years of clinical experience, and 
received approximately 40 hours of training in tobacco cessation and MAPS.
2.3. Interventions
All participants received Spanish-language self-help materials addressing alcohol and 
tobacco use51,52 and up to seven telephone counseling calls, which lasted approximately 
20-30 minutes each, and occurred within 26 weeks of the Baseline assessment. The sessions 
were usually completed over the six month time frame. Sessions typically occurred more 
often in the beginning as participants attempted to set a quit date, with more time elapsing 
between sessions as the treatment progressed. For participants willing to set a quit date, a 
typical call schedule included two pre-quit calls, one call on the quit day, and four calls post-
quit day. However, is important to highlight that MAPS is characterized by a patient-
centered approach, and as such, the timing of each call was flexible, based on the 
participant's individual needs and negotiated together by the participant and counselor.
In brief, S-MAPS utilized motivational enhancement techniques to increase motivation to 
change smoking behavior and enhance participant's self-efficacy to make a quit attempt35. In 
addition, S-MAPS utilized skills training and problem solving techniques to assist 
participants in initiating and maintaining their quit attempts, and in recovering from 
lapses16,34. In the S-MAPS group, the Wellness Program addressed treatment goals related 
to smoking abstinence as well as other relevant issues for the participant. Importantly, this 
treatment approach underscore participant's language to help guide the course of the 
treatment from moment-to-moment and determine when to shift from a motivational to a 
skill-building focus, and vice versa (for details see Vidrine et al., 2013)36.
The content of MAPS+ was identical to S-MAPS with respect to smoking cessation. 
Additionally, MAPS+ incorporated discussion of at-risk drinking and the counselor 
encouraged the inclusion of reducing at-risk drinking as a goal in the Wellness Program. 
Typically, the introduction of alcohol use in MAPS+ occurred in relation to participant's 
smoking patterns (e.g. contexts in which they smoke, past relapses). If alcohol use was not 
brought up by the participant, the counselor would note that drinking is a common 
antecedent of smoking and would inquire about how drinking might influence the 
participant's smoking in order to introduce the topic. In MAPS+, the topic of at-risk drinking 
was raised in each session by the counselor if the participant themselves did not raise it. In 
S-MAPS, the counselor never raised the issue of at-risk drinking, but would be responsive to 
its discussion as a trigger for smoking (similarly to other triggers like stress, etc.) if the issue 
was raised by the participant.
To ensure treatment fidelity and monitor drift from the protocol, all counseling sessions were 
recorded, and two randomly selected sessions per month per counselor were coded using a 
modified version of the Motivational Interviewing Treatment Integrity Code 3.1.1(MITI)53. 
Additionally, the supervisor assessed intervention fidelity by assuring that the counselor 
raised the discussion of at-risk drinking only in the MAPS+ sessions.
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2.4. Measures
2.4.1. Demographic and tobacco-related variables at baseline—Demographic and 
tobacco-related variables collected at Baseline included age, gender, partner status, 
education, employment status, income, daily smoking rate, and time to first cigarette upon 
awakening. Daily smoking rate and time to first cigarette comprised the Heaviness of 
Smoking Index (HSI)54.
2.4.2. Drinking Outcomes—Drinking outcomes included indicators of at-risk drinking 
within the past 30 days. Specifically, to assess heavy drinking, participants were asked to 
indicate how many drinks they consumed on average each day of the week. To assess binge 
drinking, participants were asked how many times they consumed four or more drinks (for 
females) and five or more drinks (for males) in one occasion. To assess drinking and driving, 
they were asked how many times they drove after consuming three or more drinks. Raw data 
were categorized to identify respondents that met criteria for one or more at-risk drinking 
indicators, as defined in the eligibility criteria. For instance, primary drinking outcomes 
were: (a) number of at-risk drinking behaviors for which the person met criteria; (b) average 
number of drinks per day; (c) number of binge drinking episodes; and, (d) number of 
drinking and driving episodes. Secondary drinking outcomes were dichotomous indicators 
of whether the person met criteria (yes/no) for: (a) overall at-risk drinking (meeting criteria 
for either heavy drinking, binge drinking, or drinking and driving); (b) heavy drinking - an 
average of ≥ 2 drinks per day (males) or ≥ 1 drink per day (females); (c) binge drinking - 
two or more occasions of consuming ≥ 5 drinks (males) or ≥ 4 drinks (females); and (d) 
drinking and driving - one or more occasions of driving after consuming ≥ 3 drinks.
Drinking outcomes were measured at each follow-up (weeks 12, 26 and 52).
2.4.3. Smoking Outcomes—Smoking status was defined as a seven-day point 
prevalence smoking abstinence, indicated by a self-report of not smoking during the 
previous 7 days. Smoking outcomes were measured at each follow-up (weeks 12, 26 and 
52).
2.5. Data Analysis
Descriptive statistics, chi-square tests, and t-tests were used to describe the sample and 
examine between-group differences in Baseline demographic characteristics, tobacco use, 
and at-risk drinking behaviors. Because all of the outcome measures were repeated over time 
and correlated within subjects, the data analytic approach utilized generalized linear mixed 
model (GLMM) regression55,56. For continuous outcomes, linear mixed models (LMMs) 
were fitted. For binary outcomes, GLMM with logit link and binomial variance functions 
were used. All tests were two-sided.
To examine treatment effects at the end of the intervention and beyond, the main effect of 
treatment condition (S-MAPS vs. MAPS+) on each of the primary and secondary at-risk 
drinking outcomes over time (i.e., weeks 26 and 52) was tested after adjusting for time, 
demographics [age, gender, partner status, education, employment and income], smoking 
status (at week 12) and the baseline measure of the specific outcome being analyzed (e.g., 
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average drinks/day). Additionally, to evaluate the effect of treatment on coaction between 
smoking and alcohol use, the interaction between treatment and smoking status at week 12 
was tested to prospectively predict the reduction of at-risk drinking overtime (i.e., weeks 26 
and 52) after adjusting for time, the same covariates, treatment, and week 12 smoking status.
To evaluate treatment effects on smoking outcomes over time, analyses included treatment 
condition (S-MAPS vs. MAPS+) as the predictor, adjusted for time, demographics, and 
baseline HSI. An intent-to-treat imputation procedure was utilized for smoking outcomes 
whereby participants lost to follow-up were treated as smokers. This approach was 
compared with a “Completers only” analyses.
3. Results
3.1. Participants characteristics and follow-up rates
There were no group differences in demographics, tobacco use, or at-risk drinking behaviors 
at Baseline (Table 1). Follow-up rates were 79% (n = 160) at week 12, 73% (n = 148) at 
week 26, and 67% (n = 136) at week 52. Over 68% of the sample completed all seven 
counseling calls, and 82.1% completed at least 4 of the 7 calls. Follow-up rates and 
completion of counseling sessions did not differ by treatment group (Figure 1; X2=4.65, df 
(3); p < .05).
3.2. Drinking Outcomes
The main effect of treatment condition was not statistically significant for any of the primary 
or secondary at-risk drinking outcomes (Table 2). However, the interaction between 
treatment condition and smoking status at week 12 (coaction) was significant for multiple at-
risk drinking outcomes (Table 2). Specifically, the treatment by smoking status interaction 
significantly predicted the primary outcomes of number of at-risk drinking behaviors and 
number of binge drinking episodes, and the secondary outcomes of meeting criteria for 
heavy drinking and binge drinking (Table 2).
Follow-up analyses of the significant interactions revealed that MAPS+ increased the 
likelihood of reducing various at-risk drinking behaviors compared to S-MAPS, but only 
among smokers who successfully quit, as predicted by the coaction hypothesis. Figure 2 
illustrates the reduction of at-risk alcohol drinking patterns for the treatment conditions by 
smoking status. For smoking abstainers at week 12, MAPS+ was significantly more 
efficacious than S-MAPS in reducing the number of at-risk drinking behaviors (B= −0.560; 
95% CI = −1.067, − 0.053; p = 0.031) and the odds of meeting criteria for heavy drinking 
(OR= 0.042; 95% CI = 0.003, 0.579; p = 0.018), and approached significance for reducing 
the odds of meeting criteria for binge drinking (OR= 0.214; 95% CI = 0.043, 1.060; p = 
0.059), but was not statistically significant in reducing the number of binge drinking 
episodes (OR= −1.42; 95% CI = −3.40, 0.56; p = 0.159). Among smokers at week 12, 
MAPS+ did not reduce the total number of at-risk drinking behaviors (B= 0.158; 95% CI = 
−0.126, 0.442; p = 0.276), number of binge drinking episodes (B= 1.092; 95% CI = −0.015, 
2.199; p = 0.053), the likelihood of meeting criteria for heavy drinking (OR= 1.513; 95% CI 
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= 0.490, 4.667; p = 0.471), or the likelihood of meeting criteria for binge drinking (OR= 
1.842; 95% CI = 0.802, 4.233; p = 0.150).
3.3. Smoking Outcomes
As expected, there were no effects of treatment condition on smoking abstinence overtime or 
at any single time point when examining intent-to-treat or completers only analyses, 
including after controlling for demographics and HSI (all p's > .05).
4. Discussion
MAPS+, a theoretically and empirically-based intervention to simultaneously treat smoking 
and at-risk alcohol use, showed promise in reducing at-risk drinking behaviors among Puerto 
Rican smokers, but only among those individuals who were able to quit smoking. These 
effects are consistent with treatment enhanced coaction. Among those individuals who quit 
smoking, MAPS+ reduced the overall number of at-risk drinking behaviors and the 
likelihood of meeting criteria for heavy drinking relative to S-MAPS, and appeared 
promising for reducing binge drinking, although the treatment effect was not significant. 
MAPS+ did not improve drinking outcomes among individuals who were unsuccessful at 
quitting smoking.
Contrary to our hypotheses, MAPS+ did not have a significant main effect on reducing at-
risk drinking relative to S-MAPS. Notably, both groups showed substantial declines in at-
risk drinking behaviors from screening to week 12 and those declines were sustained across 
the entire one year follow-up period. The findings demonstrating considerable reductions in 
drinking behaviors in both treatment groups is consistent with results from Kahler et al.27, 
one of the few other trials explicitly designed to address drinking in the context of a smoking 
cessation intervention. Together, these results suggest that participants receiving smoking 
cessation treatments may learn and apply principles and skills for behavior change that apply 
across behaviors, or that such participants may be motivated for changing multiple behaviors 
(at least with respect to smoking and drinking). Importantly, however, the current study 
found that the reductions in at-risk drinking differed among those who continued to smoke 
and those who successfully quit only when treatment specifically addressed the reduction of 
drinking. That is, there was evidence for MAPS+ induced coaction related to successful 
smoking cessation and declines in at-risk drinking, but not coaction related to abstinence 
from smoking per se57,58. These findings are consistent with previous research indicating 
that higher levels of coaction typically occur among participants receiving treatments 
designed to promote multiple behavior change compared to usual care or control 
groups21,23, and indicate that further research is needed to elucidate the natural history of 
alcohol use among smokers attempting to quit.
Our findings uniquely contribute to the literature26,59-61 by suggesting that concurrent 
treatment for at-risk alcohol use in the context of smoking cessation treatment may facilitate 
coaction. Given that coaction has typically been examined in the context of stage-based 
interventions, this study also contributes to the dearth of research addressing coaction in the 
context of other theoretically-driven approaches21,23. MAPS-based interventions specifically 
target behavior change in an integrated and holistic way by addressing substance use within 
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the context of general life stressors and regardless of the individual's motivation to change36. 
By taking a broad, holistic approach to treatment, MAPS-based interventions may be a 
particularly appropriate approach for addressing multiple risk factors simultaneously. The 
results also indicate that integrating an alcohol intervention into smoking cessation treatment 
does not undermine smoking outcomes (or improve them either)26,27. Given the phone-
based nature of the intervention, our findings are consistent with current recommendations 
that quitlines should offer alcohol counseling to smokers who exhibit hazardous drinking62, 
and particularly so among successful quitters.
4.1. Strengths and Limitations
To the best of our knowledge, this research is the first randomized controlled trial evaluating 
a combined behavioral intervention for at-risk drinking and smoking cessation among a 
Latino group, and one of the few addressing at-risk drinking in the context of a smoking 
cessation treatment, rather than focusing on smoking cessation among alcohol dependent 
individuals. Long term follow up, and satisfactory follow-up rates were also strengths.
Findings should be interpreted in light of some limitations. Results may not be generalizable 
to individuals from other racial/ethnic groups and/or dependent drinkers. Applicability to 
Puerto Ricans living in the U.S. as well as other Latino subgroups also awaits verification. 
Also, the sample size may be considered small and precluded formal examination of the 
mechanisms of coaction effects. Finally, this study examined self-reported abstinence from 
both tobacco and alcohol63,64; thus, future studies should utilize additional methodologies 
including biochemical markers or other corroborating data sources19,65.
4.2. Conclusion
The present study addresses the need for treatments targeted at changing multiple addictive 
behaviors (i.e., smoking and at-risk alcohol use), and does so through telephone counseling, 
a population-based delivery mechanism that is ubiquitous throughout the U.S. and Puerto 
Rico. Findings suggest that integrating an alcohol intervention into smoking cessation 
treatment does not reduce engagement in smoking cessation treatment, does not hinder 
smoking cessation outcomes, and can positively impact at-risk drinking among individuals 
who successfully quit smoking. Findings of coaction between smoking and drinking speak 
to the promise of multiple health behavior change interventions for substance use treatment 
and chronic disease prevention19,20.
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Highlights
• Study tested the efficacy of concurrently treating smoking and at-risk drinking
• Motivation And Problem Solving (MAPS+) was the enhanced intervention in 
the study
• There was no main effect of treatment on at-risk drinking or smoking 
outcomes
• Smoking status moderated the effect of MAPS+ on several at-risk drinking 
behaviors
• Findings are consistent with treatment enhanced coaction for smoking and 
drinking
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Figure 1. 
CONSORT flowchart of recruitment, randomization, attendance and follow-ups. S-MAPS = 
Standard Motivation And Problem Solving treatment for smoking cessation; MAPS + = 
Motivation And Problem Solving for smoking cessation plus at-risk alcohol use
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Figure 2. 
At-risk drinking behaviors by treatment group and smoking status.
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